Casimersen, marketed under the brand name Amondys 45, is a medication designed to treat Duchenne muscular dystrophy (DMD) in patients with a specific gene mutation. Casimersen was approved by the U.S. Food and Drug Administration (FDA) on February 25, 2021. The approval was granted on an accelerated basis, which means that while initial studies showed positive responses, further clinical trials are required to confirm its long-term benefits.
Uses:
Administration:
Before Taking Casimersen:
Potential Side Effects:
Patients should report any side effects to their healthcare provider or directly to the FDA at 1-800-FDA-1088.
Usual Adult and Pediatric Dose for Muscular Dystrophy:
Missed Dose:
This medication provides a targeted treatment option for patients with Duchenne muscular dystrophy who have a specific genetic mutation. As with any treatment, it is important for patients to discuss their medical history and potential risks with their healthcare provider to ensure safe and effective use. Continued research and clinical trials will further elucidate the long-term benefits and effectiveness of casimersen.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!